|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||89.27 - 91.80|
|52 Week Range||84.25 - 147.17|
|PE Ratio (TTM)||24.62|
|Earnings Date||May 4, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||115.62|
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Celgene Corporation securities between September 12, 2016 and February 27, 2018 .
Gilla Kaplan, Ph.D., Celgene’s longest-standing Director, is retiring from the Board and will not stand for reelection at the upcoming Annual Meeting of Stockholders to be held on June 13, 2018. Patricia “Pat” Hemingway Hall and Hans Bishop have been elected to Celgene’s Board of Directors. Dr. Kaplan has served as Director since April 1998.
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...
In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.
NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Celgene Corporation plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company’s website at www.celgene.com.